These five physicians are making significant contributions at the forefront of gastroenterology.
If you’d like to nominate a physician, please email pnewitt@beckershealthcare.com.
Bincy Abraham, MD
Dr. Abraham is a professor of clinical medicine and director of the Fondren Inflammatory Bowel Disease Program in the division of gastroenterology and hepatology at Houston (Texas) Methodist Weill Cornell Medical College. Dr. Abraham is a nationally recognized expert in ulcerative colitis and Crohn’s disease. She has led numerous clinical trials focused on innovative therapies for inflammatory bowel disease. In a recent Gastroenterology Advisor article, she discussed key findings on IBD therapies presented at ACG 2024.
Gregory Brennan, MD
Dr. Brennan is a senior physician at GI Alliance in Mansfield, Texas, and is currently serving as medical director for gastroenterology and endoscopy at Texas Health Mansfield Hospital. Dr. Brennan specializes in gastroenterology, IBD and endoscopic retrograde cholangiopancreatography. His research portfolio includes clinical trials and meta-analyses. As senior author, he recently published a study in Inflammatory Bowel Diseases evaluating the safety and efficacy of Upadacitinib in treating acute severe ulcerative colitis.
Philip McAndrew, MD
Dr. McAndrew is the medical director for endoscopy and infusion at University Gastroenterology in Providence, R.I. Dr. McAndrew serves as a co-investigator on a large-scale clinical trial examining ozanimod for moderate to severely active ulcerative colitis. The study focuses on patient quality of life, biomarker response and real-world safety and efficacy.
Sarah McGill, MD.
Dr. McGill is a gastroenterologist and endoscopist at UNC Health in Chapel Hill, N.C. Dr. McGill recently led a study published in Clinical Gastroenterology & Hepatology investigating a new therapy to prevent recurrent Clostridioides difficile infections. The study found that this novel treatment may be less effective than standard therapies in preventing severe disease over time.
Kathryn Peterson, MD
Dr. Peterson is a professor of gastroenterology at University of Utah Health’s department of internal medicine who specializes in diagnosing and treating diseases of the digestive system including Eosinophilic Esophagitis, Barrett’s Esophagus and inflammatory bowel disease. She co-authored a New England Journal of Medicine article on the efficacy and safety of benralizumab for patients with eosinophilic esophagitis.
